Evidence map›Paper›PMID 38753764›Full record

Trial reportPloS one2024

Validity of remote live stream video evaluation of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.

Linda P Lowes, Lindsay N Alfano, Megan A Iammarino, Natalie F Reash, Kathryn Giblin, Larry Hu, Lixi Yu, Shufang Wang, Rachel Salazar, Jerry R Mendell

2 registry-linked trialsAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03375164 phase1 / phase2completednot on this map

Systemic Gene Delivery Phase I/IIa Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MHCK7.Micro-dystrophin (microDys-IV-001)

TypeinterventionalSponsorSarepta Therapeutics, Inc.Ran2018 to 2023Enrolled4ConditionsDuchenne Muscular DystrophyArmsdelandistrogene moxeparvovec
NCT03769116 phase1 / phase2completednot on this map

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial for Duchenne Muscular Dystrophy Using SRP-9001

TypeinterventionalSponsorSarepta Therapeutics, Inc.Ran2018 to 2023Enrolled41ConditionsMuscular Dystrophy, DuchenneArmsdelandistrogene moxeparvovec, placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Linda P LowesCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.ORCID 0000-0003-4206-0557
Lindsay N AlfanoCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.
Megan A IammarinoCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.ORCID 0000-0003-2800-3855
Natalie F ReashCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.
Kathryn GiblinSarepta Therapeutics, Inc., Cambridge, Massachusetts, United States of America.
Larry HuSarepta Therapeutics, Inc., Cambridge, Massachusetts, United States of America.
Lixi YuSarepta Therapeutics, Inc., Cambridge, Massachusetts, United States of America.
Shufang WangSarepta Therapeutics, Inc., Cambridge, Massachusetts, United States of America.
Rachel SalazarSarepta Therapeutics, Inc., Cambridge, Massachusetts, United States of America.ORCID 0000-0002-0644-5954
Jerry R MendellCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conducting functional assessments remotely can help alleviate the burden of in-person assessment on patients with Duchenne muscular dystrophy and their caregivers. The objective of this study was to evaluate whether scores from remote functional assessment of patients with Duchenne muscular dystrophy correspond to in-person scores on the same functional assessments. Remote live stream versus in-person scores on the North Star Ambulatory Assessment (including time [seconds] to complete the 10-meter walk/run and time to rise from the floor [supine to stand]) were assessed using statistical analyses, including intraclass correlation coefficient, and Pearson, Spearman, and Bland-Altman analyses. The remote and in-clinic assessments had to occur within 2 weeks of one another to be considered for this analysis. This analysis included patients with Duchenne muscular dystrophy, aged 4 to 7 years. Participants in this analysis received delandistrogene moxeparvovec (as part of SRP-9001-101 [Study 101; NCT03375164] or SRP-9001-102 [Study 102; NCT03769116]) or were randomized to receive placebo (in Part 1 of Study 102). This study evaluates score reproducibility between live stream remote scoring versus in-person functional assessments as determined by intraclass correlation coefficient, and Pearson, Spearman, and Bland-Altman analyses. The results showed that scores from remote functional assessment of patients with Duchenne muscular dystrophy strongly correlated with those obtained in person. These findings demonstrate congruence between live stream remote and in-person functional assessment and suggest that remote assessment has the potential to reduce the burden on a family by supplementing in-clinic visits.

Indexed as

Muscular Dystrophy, DuchenneChildChild, PreschoolFemaleHumansMaleReproducibility of ResultsTelemedicineVideo Recording

Identifiers

PMID38753764
PMCPMC11098514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.